Monitor for the planned Q4 2026 IND submission and any subsequent FDA feedback, which would be the next major catalyst. The $4.0M cash runway is thin for a pre-clinical biotech — watch for future equity financing needs that could dilute common shareholders.
Price Chart
Executive Summary
Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with lead candidate Phyto-N for ulcerative colitis, including completion of GMP pilot-scale manufacturing and a dose-range finding toxicology study with no adverse findings. The company also expanded its pipeline strategy to include cancer cachexia and reported $4.0 million in cash as of March 31, 2026, which management believes is sufficient to fund IND-enabling activities through a planned Q4 2026 IND submission. No financial results or guidance were provided, and the filing is a routine preclinical-stage update with no material financial data.
Key Facts
- Completed GMP pilot-scale manufacturing of Phyto-N in February 2026
- Completed 28-day dose-range finding toxicology study in rats and dogs with no treatment-related adverse findings
- Planned IND submission for Phyto-N in ulcerative colitis targeted for Q4 2026
- Expanded pipeline strategy to include cancer cachexia as a new core indication
- Cash and cash equivalents of approximately $4.0 million as of March 31, 2026
- Global cancer cachexia market estimated at $2.54 billion in 2024, projected to reach $3.90 billion by 2033 per Grand View Research
Financial Impact
No financial results reported; cash position of $4.0 million disclosed
Risk Factors
- Pre-revenue stage with no approved products; clinical and regulatory risks remain high
- Cash runway of $4.0 million may require additional financing before IND submission or Phase I initiation
- Phyto-N is still in preclinical development; IND may not be allowed to proceed by FDA
- Cancer cachexia pipeline expansion is exploratory with no near-term catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022898 |
| Exhibit: ex99-1.htm | 0001493152-26-022898 |
| Document: 0001493152-26-022898-index-headers.html | 0001493152-26-022898 |
| Document: 0001493152-26-022898-index.html | 0001493152-26-022898 |
| Document: 0001493152-26-022898.txt | 0001493152-26-022898 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $4.77 | awaiting T+20 | — | $4.76 (−0.00%) |
Aug 17, 2026 10w ago | 8-K | $4.44 $4.37 | ▼ −1.69% | ▼ −0.70% | $4.76 (+7.32%) |
May 14, 2026 23w ago | 8-K | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.76 (+1422.33%) |
May 14, 2026 23w ago | Press Release | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.76 (+1422.33%) |
May 7, 2026 24w ago | 8-K | $0.3160 $0.3260 | ▲ +3.16% | ▲ +0.03% | $4.76 (+1407.88%) |
Apr 2, 2026 29w ago | 8-K | $0.4900 $0.4170 | ▼ −14.90% | ▼ −24.77% | $4.76 (+872.43%) |
Mar 30, 2026 30w ago | Press Release | $0.5110 $0.4300 | ▼ −15.85% | ▼ −25.27% | $4.76 (+832.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers